scholarly journals A Review of the Treatment of Type 2 Diabetes in Children

2015 ◽  
Vol 20 (1) ◽  
pp. 4-16 ◽  
Author(s):  
Erin St. Onge ◽  
Shannon A. Miller ◽  
Carol Motycka ◽  
Adrienne DeBerry
Keyword(s):  
Type 2 Diabetes ◽  
American Diabetes Association ◽  
Clinical Evidence ◽  
Endocrine Society ◽  
Adequate Treatment ◽  
Oral Medications ◽  
Diet And Exercise ◽  
Microvascular And Macrovascular Complications ◽  
Diabetes And Obesity

The incidence of type 2 diabetes and obesity in children and adolescents has risen at staggering rates. Studies have shown that treating type 2 diabetes with oral medications in children may be more difficult than treating in adults. Compounding this problem is the fact that most of the medications available for treating type 2 diabetes have not been studied in children. Recently, the American Diabetes Association and the Pediatric Endocrine Society have collaborated to create a guideline for the treatment of type 2 diabetes in children. Similar to the treatment of adults with type 2 diabetes, metformin remains the mainstay of therapy along with diet and exercise. Adjunctive therapy should be based on the limited clinical evidence available as well as on patient preference. In order to avoid detrimental microvascular and macrovascular complications, patients, clinicians, and family members should work together to ensure adequate treatment of type 2 diabetes in children.

Dapagliflozin: A new class of drug in the treatment of Type 2 diabetes

2016 ◽  
Vol 2 (3) ◽  
pp. 157-159
Author(s):  
N. Surendra Reddy ◽  
P. Lakshmi ◽  
G. Divya ◽  
T. S. Durga Prasad ◽  
D. Ranganayakulu
Keyword(s):  
Type 2 Diabetes ◽  
New Class ◽  
Oral Medications ◽  
Urinary Glucose ◽  
Diet And Exercise ◽  
The Us ◽  
The Common ◽  
Tract Infections ◽  
Glucose Excretion

Sodium-glucose co-transporter (SGLT) inhibitors are a new group of oral medications used for treating type 2 diabetes. Dapagliflozin was approved in January 8th, 2014 and is the second selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2) to be marketed in the US. It is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 Diabetes Mellitus (T2DM).It is available 5mg and 10 mg in film coated tablets. It acts by inhibiting SGLT2 decreases plasma glucose by increasing urinary glucose excretion. The common adverse reactions are genital mycotic infection, nasopharyngitis, urinary tract infections, back pain, urination increase, nausea, influenza. It is contraindicated in hypertension, renal impairment, hypoglycemia, genital myotic infections and bladder cancer.

Sign in / Sign up

Export Citation Format

Share Document